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ABSTRACT 
Purpose: I studied the effects of various treatments for benign prostatic hyperplasia on urethral 
resistance. 
Materials and Methods: I reviewed the literature on urodynamic effects of treatments for 
benign prostatic hyperplasia. Articles that reported pretreatment and posttreatment values of 
relevant urdynamic parameters were analyzed. Average before and after treatment values of 
maximum flow rate and detrusor pressure at  maximal flow rate for every study were plotted on 
an Abrams-Griffiths nomogram and classified as obstructed, equivocal or nonobstructed. Average 
values of maximum flow rate and detrusor pressure at maximal flow rate were calculated for the 
total number of patients treated by a certain modality. 
Results: Based on this analysis, the rank order of d y n a m i c  efficacy was that open prostatectomy 
is more effective in reducing urethral resistance than is transurethral prostatedomy. These treat- 
ments diminish obstruction better than laser treatment or transurethral incision of the prostate, 
which again are more effective than balloon dilation, a-blockers or transurethral microwave ther- 
motherapy. Finally, androgen deprivation performs better than placebo treatment. 
Conclusions: The rank order of urodynamic efficacy as determined in this analysis shows a high 
level of agreement with reported rank order of symptomatic efficacy of various modalities. After 
placebo treatment there is no significant change in urethral resistance. This finding indicates 
that pressure-flow studies are a sensitive way to compare active to placebo treatment and that 
pressure-flow studies have excellent long-term reproducibility. 
Kcr WORDS: bladder, prostatic hypertrophy, urodynamics, treatment outcome 
The role of pressure-flow studies in the evaluation of treat- 
ments for benign prostatic hyperplasia (BPH) is controver- 
sial. The third international consultation on BPHl and the 
Agency for Health Care Policy and Research (AHCPR) clini- 
cal practice guidelines2 have included pressure-flow studies 
as an optional diagnostic test in their algorithms for the 
evaluation of patients with symptoms suggestive of prostat- 
ism. These algorithms refer to clinical diagnostic situations. 
However, the American Urological Association (AUA) new 
technology assessment committee,3 which looks at  the eval- 
uation of new treatments has made the following state- 
ment: “Detrusor pressure flow studies should be done on as 
many patients as possible, and at minimum, in a subgroup 
of at  least 30 patients.”3 In the assessment of the value of 
pressure-flow studies in the evaluation of BPH treatment, 
several questions arise. Are pressure-flow studies repro- 
ducible? What is known about urodynamic results of var- 
ious treatment modalities? Should the effect on parame- 
ters measured during pressure-flow studies be considered 
a treatment outcome? Is it possible to rank treatments 
according to urodynamic efficacy? Is urodynamic improve- 
ment correlated with symptomatic improvement? This re- 
view tries to answer these questions. 
DEFINITION OF URETHRAL RESISTANCE AND URODYNAMIC 
OBSTRUCTION 
During a pressure-flow study, detrusor pressure and uri- 
nary flow rate are measured simultaneously. The main chal- 
lenge in interpreting these data is to separate contributions 
of the bladder and outflow tract to these 2 measures in order 
to generate independent parameters for detrusor contraction 
strength and urethral resistance. A pressure-flow study can 
be represented graphically by an X-Y plot in which detrusor 
pressure is plotted against flow rate throughout voiding 
(fig. 1). A high detrusor pressure at maximum flow rate 
in combination with relatively low maximum flow rate char- 
acterizes the typically obstructed patient (fig. 1, plot A). 
A flat plot such as C in figure 1 indicates that the patient is 
unobstructed. Many plots, however, are intermediate and 
more difficult to classify (fig. 1, plot B). 
Several methods to analyze and interpret the pressure flow 
data have been developed. Three of these methods have been 
used in larger outcome studies of BPH treatment by authors 
other than the developer of the method.4-7 These methods try 
to reduce the data content of a pressure-flow plot to 1 number 
or 1 parameter, or 1 straight line characterized by 2 param- 
eters. A fourth method, the so-called “3 parameter modeP 
has not been used in larger outcome studies by authors other 
than the developer of the method.9 
The Abrams-Grifiths nomogram. Pressure-flow plots can 
be drawn on an Abrams-Griffiths nomogram.4 The develop- 
ers of this nomogram have drawn 2 lines that separate an 
obstructive from an equivocal area and the equivocal from 
the unobstructed zone, respectively (fig. 1). These lines were 
drawn on the basis of clinical judgment of which patients 
were truly obstructed and which patients were not. The data 
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FIG. 1. Abrams-Griffiths nomogram with examples of obstructed 
(A), equivocal ( B )  and unobstructed (C) pressure-flow plots. Exam le 
of linear passive urethral resistance relation line is drawn, in tLs 
case for plot B. Point where this straight dotted line intersects with 
Y-axis is value of minimal urethral opening pressure. Exam le of 
adratic urethral resistance factor function is +so fitted to pfot B. 
g i n t  where this curved dashed line intersects with Y-axis is value of 
urethral resistance factor. 
point that represents the value of detrusor pressure at max- 
imum flow rate can be used to classify patients as obstructed, 
equivocal or unobstructed (fig. 1, points A to C). 
The group-specific urethral resistance factor. Griffiths et  a1 
have stated that “although it is impossible to give a univer- 
sally valid definition of urethral resistance, the existence of a 
valid group-specific resistance factor means that, within a 
particular group, the value of the resistance factor is the 
urethral resistance, thus defining it q~antitatively.”~ Based 
on statistical evaluation of a large number of voidings, a 
quadratic curve can be computed and fitted through detrusor 
pressure at maximum flow rate (for example the curved 
dashed line through point B on fig. 1). The intersection of this 
curve with the vertical axis indicates the value of Griffiths’ 
urethral resistance factor.5 Rollema and Van Mastrigt have 
classified patients as obstructed or nonobstructed on clinical 
grounds and subsequently determined the discrimination 
value of urethral resistance factor. This value was set at  such 
a level that sensitivity and specificity of the parameter in 
separating obstructed from nonobstructed patients were 
equal. The discrimination limit of urethral resistance factor 
was found to be 29 cm. water.10 Patients with a preoperative 
value below this showed only small decreases of urethral 
resistance factor after transurethral resection of the pros- 
tate. 
The Schafer nomogram and linear passive urethral resis- 
tance relation. Schafer et a1 have introduced the linear pas- 
sive urethral resistance relation.6 This is a straight line that 
can be drawn through detrusor pressure at maximum flow 
rate and the lowest pressure at which flow can be detected. 
The latter point is also called the passive urethral resistance 
Elation footpoint or minimal urethral opening pressure (see 
straight dotted line through point B on fig. 1). The linear 
passive urethral resistance relation is characterized by the 
value of minimal urethral opening pressure and its slope. 
Gehiifer has devised a nomogram that divides the whole 
Spectrum of possible urethral resistance values into 7 classes 
called 0 to VI.7 He contended that values of minimal urethral 
owning pressure below 20 em. water were not further re- 
duced by therapy and that therefore these patients were not 
obstructed before the initiation of therapy. The value of min- 
mal urethral opening pressure is reported in several studies, 
whereas linear passive urethral resistance relation classes 
have been reported less frequently. 
Since the cutoff values that are being used to indicate 
whether a patient is obstructed are somewhat arbitrarily 
chosen (except maybe for the borderline between classes 0 
ind I in the Schtifer nomogram), it seems more appropriate to 
inalyze outcome data on the basis of changes in urethral 
mesistance that occur after intervention. There is a high de- 
pee of agreement between the aforementioned 3 methods 
md for clinical purposes there are no important differences 
xtween them. ‘1 
MATERIAL AND METHODS 
English language articles on the urodynamic effects of 
treatments for BPH that were published before July 1996 
were identified by an extensive MEDLINE search starting 
from 1966, a search of reference lists of review articles pub- 
lished in that period and a hand search starting January 
1990 of lists of contents from The Journal of Urology, Uml- 
ogy, The British Journal of Urology, Neurourology and 
Urodynamics, The Scandinavian Journal of Urology and Ne- 
phrology. Articles were read if the abstract indicated that 
urodynamic or pressure-flow studies had been performed. 
Only articles that included quantitative data from pressure- 
flow studies before and after treatment were subsequently 
included in this analysis. If the pretreatment and posttreat- 
ment values of maximum flow rate and the corresponding 
detrusor pressure at maximum flow rate are reported, it  is 
possible to depict results of treatment graphically by plotting 
average pretreatment and posttreatment detrusor pressure 
at  maximum flow rate values on an  Abrams-Griffiths nomo- 
gram. 
In some articles the authors report maximum voiding pres- 
sure, maximum detrusor pressure or maximum intravesical 
pressure in combination with maximum flow rate. According 
to the International Continence Society standardization of 
terminology12 these are usually not equivalent to detrusor 
pressure at maximum flow rate. 
The data were considered to be nonevaluable if detrusor 
pressure at  maximal flow rate was only reported in combi- 
nation with a maximum free flow rate that was not measured 
at  the time of the pressure-flow study, if only the average 
flow rate was reported in combination with detrusor pressure 
at  maximum flow rate, or if pretreatment and posttreatment 
values were reported in grossly different numbers of pa- 
tients. Several other articles have only or additionally re- 
ported the pretreatment and posttreatment values of ure- 
thral resistance parameters like urethral resistance factor 
and minimal urethral opening pressure [see tables 1 to 4). 
In articles that were included in this analysis, an average 
pretreatment and posttreatment value for detrusor pressure 
at  maximum flow rate and maximum flow rate andor mini- 
mal urethral opening pressure and/or urethral resistance 
factor was either reported or could be calculated for respec- 
tive patient groups. Finally, data from all articles dealing 
with 1 particular treatment modality could be combined and 
average values for the pressure-flow parameters could be 
determined. Urodynamic effects of various treatments could 
thus be compared in large numbers of patients. 
RESULTS 
Effects of  various treatment modalities on urethral resis- 
tance. Androgen deprivation in the treatment of BPH can 
achieve reduction of prostatic volume of about 20 to 30%.13.14 
Theoretically this results in a decrease of outflow tract ob- 
struction and may lead secondarily to symptom reduction.13 
Effects of the lutehizing hormone releasing hormone ana- 
logues buserelin14 and leuprolide,15 the anti-androgens 
cyproterone acetate14 and casodex16 and of the 5-a-reductase 
inhibitor finasteride17. Is have been explored urodynamically. 
In table 1 the data of 124 men treated with various types of 
androgen deprivation are summarized. Effects of these treat- 
ments can be shown graphically on an Abrams-Griffiths no- 
mogram (fig. 2). The study of fmasteride by Tammela and 
Kontturi (line 2 on fig. W7 shows a clear effect on urethral 
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TABLE 1. Effmts on urethral resistance of medical treatment for BPH 
"&- zm MeanUrdhral 
After-w 
No. Followup MadmumFlaw Fl0wRat.e Reatawe 
RateBehd Befior$ARer F-J3eli3d M a  22; (amwater) 
Rekerm3 hlment (dodday) 
(an. water) 
(1.2mg.Ycyprotemne 8 12%. 7881 637.9 47/49 
(5mg.) 7 2Yrs. 45/32 
Anrtrogen deprkatim 
Bosch et d14 
R o b  et all8 
Tammela and h t h u i " *  
Eri and Tveter'4* caaodex (5Omg.) 14 24%. 84lao 9.018.5 
&j 4 %IS.* Leuprolide (3.75mg128) 26 24%. 79/66 5.w.4 
H d u n d  et aim.* Razoein (4mg.) 20 4%. 67/65t 4.96.9 
Wund and Andersson=.* Razoein (4mg.) 8 4%. 
Chapple et at".* Razoein (4mg.f 15 12%. 
StOttandAbramsn" 
Rouema et a P *  
Chapple et al=*t Razosio (4mg.l 12 12%. w t  729.5 
chapple et d-4 
chapple et al3'.* 
Rc@ier et a153 
Martorana et al=.* Alfuzasin (7.5mg.) 15 12%. 9w39 6.7n2.3 
Martorana et al=* (7.5 mg.) 25 12%. 7w4o 7.Wl3.1 
Risi & allS.8 TelXZ&Il (5mg.) 50 36%. 82/15 9.mo.9 
TeIXMSiU (10mg.) 33 26%. 7359 7.118.9 
r (4mg.) 44 3Mos. 94/83 ii.7n3.2 
WI* et aI= 
Gerberetal= 
Kad0wandAbrams39 ~ i t o s t e r o l  (0.3m.) 25 24%. W103 9.WO.8 
acetate (200 mg.) 
(5mg.) 19 24%. E6-87 7.7fl0.3 
Risi & d19.* (5mg.) 50 36%. 89/82 10.W0.4 
a--*blOrkers: 
7.219.2 
Indoramin (4omg.) 18 4%. 9&rs2 6.7B.4 
7 m  1/56 9.4fl2.6 
(4mg.) 16 4%. 47141 
Razosio (4mg.) 20 12%. m 10.W7 
(4mg.l 53 12%. 7m4t 9.Vl1.7 
(10mg.) 24 26%. 4455 
-drugs: 
Mean Minimal 
u-opening 
pressure Befod 
After Therapy 
(an. water) 
125% 
78166 
&1R9 
47140 
55/42 
77n2 
40/30 
97m 
79/12 
39/30 
Abrams38 eandicidixi (3ooG.) 23 6Mos. 12W12.5 7.89.2 
Numbers before author names correspond to numbers on fiaures 2 and 3. 
* Results were derived from rando& (and in most cases-placebo) controlled studies. 
t These authors have reported maximum voiding (detrusor) pressure instead of detrusor pressure at maximum flow rate. 
$ These results are from 2 different study locations reported in 1 paper. 
TABLE 2 .  Effects on urethral resistance of placebo treatment for BPH 
~ 
p r e ~ ~ ~ ~ ~ ~ u m  Mean Maximum Flow Mean Urethral Resistance Mean Minimal Urethral 
References No. Men Followup Flow Rate Before/ARer Rate BefordAfter Fador BefordAfter Opening Pressure Beford 
Therapy water) Therapy (mlJsec.) Therapy (cm. water) After Therapy (cm. water) 
Abrama* 29 6Mos. 14lJ138 8.U8.4 
Hedlund et al' 20 4%. 67163* 4.914.7 47/43 
Hedlund and Anderaaona 8 4%. 7m4* 727.6 55/54 
Chapple et al- 16 12Wks. 76/82 10.2/11.0 
Rouema et  ala 17 4%. 42/45 
Kadow and Abramss9 28 24%. 9W107 7.ff10.4 
Stott and AbramsZ7 16 4%. 1071103 7.016.6 
Chapple et a P t  16 12%. 83/84* 5.916.2 
Chapple et al"? 23 12%. 9 W *  10.W14.9 
Tammela and Kontturi" 17 24%. 115/118 8.W9.9 1131116 
E n  and Tveterl6 13 24%. 86/82 8.0R.2 7U70 
E n  and Tveter" 24 24%. 71/76 6.4l6.4 6717 1 
Chapple e t  alsl 50 12%. 74f82* 9.ll10.2 
Nielsen et d'l 6 4Mos. 72/85 10.W10.7 
Martonma et aP2 26 4%. 82/77 8.5l12.5 
Numbers before author names correspond to numbers on figum 4. 
* These authors have reported maximum voiding (detrusor) pressure instead of detrusor pressure a t  maximum flow rate. 
t These results are from 2 different study loeations reported in 1 paper. 
t Thii study involved watchful waiting. 
Martorana et also 15 4%. 100188 
de Wildt et a1424 98 6Mos. 28/26 24/22 
resistance as evidenced by an increase of maximum flow rate 
in combination with a decrease of detrusor pressure at max- 
imum flow rate. However, on average these men have not 
reached the unobstructed zone after treatment. Of individual 
patients 10 of 19 were still obstructed after 6 months of 
finasbride therapy.17 A larger study of finasteride by Risi et 
al (line 5 on fig. 2)'s who treated 50 men with the same 
average initial prostate volume (50 cm.9 as in the Tammela 
and Kontturi patients. showed only small and statistically 
insignificant change in urethral resistance after 9 months of 
treatment (line 5 on fig. 2).19 There are some unexplained 
differences between these 2 studies. Initial detrusor pressure 
at maximum flow rate in the patients of Tammela and Kont- 
turi is higher than corresponding values in Risi's cases and 
most of the other urodynamic studies of effects of BPH treat- 
ment. Also prostate volume in studies of Tammela and Kont- 
t u n  and Risi decreases from 50 to 35 gm. (30%) and from 50 
to 44 gm. (12%), respectively. Percentage decrease of prostate 
volume in both of these studies is a t  variance with the re- 
ported decrease of 19% in a large randomized study of finas- 
teride.13 Differences between these 2 studies are also evident 
when comparing effects on minimal urethral opening pres- 
sure (table 1). Glazier et a1 found that after a mean 6 months 
of treatment with finasteride a t  a dose of 5 mg. per day, 
voiding pressures had not decreased but even increased in 
74% of 39 men.20 
Prostate volume decrease after treatment with casodex 
(27%),16 leuprolide (34%)15 and buserelin or cyproterone acd 
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TABLE 3. Effects on urethral resistance offopeni prostatectomy, transurethral resection, tmnsurethrat incision and transurethral 
electrouaporization for BPH 
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References No. Men Followup Flow Rate Rate BeforeJAfter 
Therapy ( n ~ s e c . )  Press- BeforeJAfier Therapy VmL .__ r ._ -..I _ _  1 inernpy rcm. wnwr (cm. watpr) 
pmstatectomy (not specified): 
A b r a m ~ ~ ~  
Abrams et  a14' 
Open prostatectomy: 
C a s t r ~ ~ ~  
Meyhoff e t  a147.* 
1. Edwards and Powelle,* 
Meyhoff e t  a147,* 
Hellstrom et  a149,* 
Jensen et  a15' 
Neal et al"' 
Meyhoff et a154 
Sphgberg et  ale 
Rollema and Van Mastrigt'O 
Gill and Kabalins2~* 
Jung et alS3,* 
Transurethral incision: 
Edwards and pow ell'"^* 
Hellstmm et  aI4'.* 
Sirls et al'" 
Transurethral resection: 
Transurethral electrovaprization: 
100 
152 
75 
2511 
22 
34 
13 
134 
179 
11 
23 
29 
12 
43 
22 
11 
28 
4 Mos. 
Greater than 4 Mos. 
4 wks. 
6 Mos. 
6-18 wks. 
6 Mos. 
6 Mos. 
6 Mos. 
6 Mos. 
3-6 Mos. 
3 Mos. 
12 Mos. 
9 Mos. 
6-18 wks. 
6 Mos. 
12-96 Mos. 
Greater than 3 Mos. 
~ ~._., 
13U75 
132177 
92139t 
75/30 
57135 
75/40 
58/26 
60/27 
1W61 
12&79$ 
95/34 
92159 
60135 
50139 
35/35 
84/44 
7.U20.1 
6.9/19.9 
6923.5 
8.W23.0 
5.W19.2 
63/16 
7.W16.5 
9316.3 
9.0/18 
10.8'19.3 
8316.5 
8.9119.2 
9 . m 1  
5.W14.4 
8.W12.9 
7.7110.7 
41/16 
Porn et  aFO 16 2 Mos. 80137 7.2117 
Numbers or letters before author names correspond to numbers and letters on figures 5 and 6. 
* Results were derived from randomized controlled studies. 
t This author reported ''maximal intravesical pressure during micturition." 
I. These authors reported intravesical pressure at maximum flow rate. 
0 Two patients underwent transvesical and 5 retropubic prostatectomy. 
I/ All patients underwent transvesical prostatectomy. 
TABLE 4. Effects on urethral resistance of nonelectrical forms of energy delivery and miscellaneous treatments for BPH 
References 
Mean Iktrusor Mean Mean Urethral Mean Minimal 
M%mure~:w M-D mow Resistance urethral  Opening 
Treatment No. Men Followup Rate Before/ Rate Before/ Factor Before/ Pressure Beford 
Afier Therapy ARer Therapy After Therapy After Therapy 
(cm. water) (mllsec.) (cm. water) (cm. water) 
Laser prostatectomy: 
Bosch e t  aF2 
Kabalin e t  aI5'.* 
Jung et a153.* 
Jung et a153.* 
de Wildt e t  a P  
Cannon et  alM 
Cummings et  a F  
James et aP5 
Transurethral ultrasound laser 
induced prostatectomy 
Urolase 
Urolase (less than 50 cm3) 
Urolase (greater than 50 cm3) 
Transurethral ultrasound laser in- 
duced prostatectomy + visual laser 
ablation of prostate (various) 
Visual laser ablation of pmstate 
(various) 
Ultralime 
Visual laser ablation of prostate 
(various) 
Other forms of high energy 
delivery: 
Porn et Transurethral microwave thermo- 
therapy low energy 
therapy low energy 
de la Rosette e t  a170 
Venn et  a172.* 
Transurethral microwave thermo- 
Transurethral microwave thermo- 
therapy low energy 
therapy high energy 
Manieri e t  ap 
Madersbacher and 
Marberger7h 
Potts et a ~ 7 "  
Miscellaneous: 
Weiss et alR' Balloon dilation 
Cherry et a P  Balloon dilation 
Gaabathi  et al"' Balloon dilation 
Nielsen et  a141.+ Prostate spiral 
Venn et  a17*.* 
Letters before author names mrreswnd to letters on fim 6. 
Transurethral microwave thenno- 
High intensity focused ultrasound 
Transurethral needle ablation 
1 Hr. dilation to 22F 
30 
10 
32 
58 
40 
75 
25 
Less than 
61 
38 
77 
47 
31 
28 
39 
11 
28 
15 
9 
46 
3 Mos. 
12 Mos. 
9 Mos. 
9 Mos. 
6 Mos. 
26 Wks. 
3 Mos. 
3 Mos. 
12 Mos. 
6 Mos. 
3 Mos. 
6 Mos. 
3-6 Mos. 
12 Mos. 
12 wks. 
12 wks. 
24 Wks. 
4 Mos. 
2 MRS 
63/39 
91/55 
52142 
65/54 
80140 
85155 
7u54t 
70160 
74/75 
9Ygll: 
67/60 
66/55 
97/79 
84/829 
8716711 
6.631 1.2 36/21 
8.2B1.6 
6.8/17.0 
5.Yg.9 
49/19 41/17 
6.0113.7 49119 42/18 
6.U14.5 
6.310.6 
8.3/12.9 
6.8'9.0 45/40 45/41 
11.5l11.2 
7.m.7 41/31 42131 
8.5/11.5 
6.5/9.7 
7.7110.3 
88/65 6.U8.5 
R.1B.O 
Results derived fium randomizedamntrolled studies. - 
Authors r e p o d  %oi&g pressure" instead of detrusor pressure at maximum flow rate and average instead of maximum flow rate. * Authore reported median instead of mean values of detrusor pressure at maximum flow rate for total patient 
5 Authors r e p o d  'average voiding pressure" instead of dehusor pressure at maximum flow rate. 
11 Authors reported 'de-r pressure" instead of detrusor pressure at maximum flow rate. 
2038 URODYNAMIC EFFECTS OF BENIGN PROSTATIC HYF'EFU'LASIA TREATMENT 
0 5 10 15 20 25 
Max. Flow Rate (mus) 
FIG. 2. Effects of androgen deprivation on urethral resistance. 
Average pretreatment data points (closed circles) are connected with 
average posttreatment data points (open circles) for studies of buse- 
relidcypmterone acetate (line 1). finasteride (lines 2 and 5). casodex 
(line 3) and leuprolide (line 4). Numbering of lines corresponds to 
numbering of androgen deprivation studies in table 1. 
etate (29%)14 seems to be somewhat greater than that 
achieved with finasteride but urodynamic effects were 
equally small (table 1 and fig. 2). On an individual basis, 7 of 
8 patients treated with buserelin or cyproterone acetate were 
still obstructed after 3 months of therapy.14 Urethral resis- 
tance parameter was measured in 2 studies.14.1s Finasteride 
has resulted in a decrease from 45 to 32 cm. water in 7 
patients followed for 2 years.18 In a group of 8 patients 
treated with either buserelin or cyproterone acetate, urethral 
resistance factor increased from 47 to 49 cm. water after 3 
months of therapy." In both studies patients were, on aver- 
age, still classified as obstructed based on the cutoff value of 
29 cm. water.10 In 4 studies small16.19 to moderatels.17 de- 
creases of minimal urethral opening pressure were found 
(table 1). On average patients treated with androgen depri- 
vation or 5-a-reductase inhibition did not become unob- 
StrUcted. 
a-Adremptor blockers. The use of a-adrenoceptor blockade 
to treat men with BPH is based on the hypothesis that bladder 
outflow obstruction is partly determined by dynamic factors. 
These dynamic factors are determined by prostatic smooth 
muscle cell tension, which is mediated by a-1-adrenocep 
tors.21-= 
Studies on urodynamic effects of a-adrenoceptor blockers 
all show average increase of maximum flow rate in combina- 
tion with average decrease of detrusor pressure at maximum 
2 110 
0 / I I 
0 5 10 15 M 25 
Max. Flow Rate (rnL/a) 
FIG. 3. Effects of a-blocker treatment on urethral resistance. Av- 
erage pretreatment data points (closed circles) are connected with 
average posttreatment data points (open circles) for studies of pra- 
zosin (lines 1 , 2 , 3 , 5  and 6), indoramine (line 4), doxazosin (lines 7 
and ll), alfuzosin (line 8) and terazosin (lines 9 and 10). Numbering 
of lines corresponds to numbering of a-blocker studies in table 1. 
flow rate or maximum detrusor pressure (table 1 and fig. 
3).1%24-31 Comparison of data from 2 studies reported by 
Chapple et  a128 shows some interesting features, 2 sub- 
groups, 5 and 6 on fig. 3 and table 1, from different sites that 
followed the same protocol, were included in 1 article. Sur- 
prisingly, patients in study 6 showed a much larger increase 
in flow rate, which is unexplained, and patients in study 5 
were more obstructed initially.28 Excellent urodynamic re- 
sults achieved with alfuzosin in a study by Martorana et  al 
(line 8 on fig. 3) are also a t  variance with other studies of 
effects of a-blo~kers.3~ However, only about half of the men 
initially included in this study were finally evaluated urody- 
namically. With alfuzosin treatment a large average de- 
crease in minimal urethral opening pressure from 97 to 29 
cm. water has been reported by the same group.30 In a study 
of the terazosin effects the average urethral resistance factor 
values decreased from 44 to 35 cm. water, leaving patients in 
improved but still obstructed state after 6 months of treat- 
ment.33 Doxazosin treatment for 1 month resulted in an 
average decrease of urethral resistance factor from 47 to 41 
cm. water.34 Mean minimal urethral opening pressure de- 
creased moderately in studies of p r a z o ~ i n , ~ ~ . ~ ~  terazosin19.29 
and doxazosin35 but an unobstructed value was not achieved 
(table 1). 
In summary, a-blocker treatment on average results in 
decrease of urethral resistance. After treatment patient 
groups in 3 of 11 studies reached the equivocal zone of the 
Abrams-Griffiths nomogram. Patients remained in the ob- 
structed zone in the other studies. One additional study36 of 
prazosin could not be evaluated because of grossly different 
numbers of patients in which maximum flow rate and max- 
imum voiding pressure were reported. A 9-month random- 
ized comparative study of 5 mg. finasteride and 5 mg. tera- 
zosin showed greater decrease in urethral resistance in the 
terazosin group19 (line 5 on fig. 2 versus line 9 on fig. 3). 
Miscellaneous drugs. Serum cholesterol lowering agents with 
the proposed secondary effect of reabsorption of cholesterol from 
hyperplastic glands have been used for BPH treatment because 
of the higher cholesterol content of hyperplastic glands com- 
pared to normal glands.37 Double-blind placebo controlled stud- 
ies of candicidin in a dose of 300 mg. per day and of psitosteryl 
pD-glucoside in a dose of 0.3 mg. per day showed that 6 months 
of treatment with these drugs had effects on urethral resistance 
that were statistically not significantly different from effects of 
placebo (table l).38*39 
Placebo arms of (medical) treatment protocols. In controlled 
trials of pharmacologic treatment, a large placebo effect of 
more than 40% has been observed on symptoms suggestive of 
BPH.40 Table 2 and figure 4 show results obtained in 14 
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FIG. 4. Effects of placebo treatment on urethral resistance. Aver- 
age pretreatment data points (closed circles) are connected with 
average posttreatment data points (open circles) for studies of which 
numbering of lines corresponds to numbering of placebo studies in 
table 2. 
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placebo treatment arms. Flow rate slightly increased in 7 
s t ~ d i e ~ 1 ~ , ~ ~ . ~ ~ . ~ ~ , ~ ~ , ~ ~ , ~ ~  and slightly decreased or remained 
the same in 6 studies.l5.l6.24.27.38,4l With the exception of 
study 828 and study 1432 (table 2), differences in position on 
the Abrams-Grifiths nomogram before and after treatment 
are minimal, which indicates that urethral resistance does 
not change, and that on average pressure-flow studies are 
reproducible. The relatively large increase in flow rate with- 
out change in detrusor pressure in studies 8 and 14 is unex- 
plained. 
In the placebo arm of a controlled study of the effects of 
doxazosin, mean urethral resistance factor value increased 
slightly from 42 to 45 cm. water after 1 month.34 Mean 
minimal urethral opening pressure did not change signifi- 
cantly in 2 placebo arms of a-blocker studies24325 and of 3 
studies using androgen deprivation (table 2).1"17 de Wildt et 
aP2 have studied effects of watchful waiting in 98 patients 
with symptoms suggestive of BPH. After a 6-month period 
average values of urethral resistance factor and minimal 
urethral opening pressure showed only negligible changes 
(table 2). 
OPEN PROSTATECTOMY 
In open prostatectomy the prostatic adenoma is removed 
surgically, either retropubically, that is through an incision 
of the surgical capsule of the prostate, or transvesically." 
In 2 studies by Abrams et a1 the type of prostatectomy was 
not clearly specified.44.45 In these studies, which on average 
involved patients who were clearly obstructed initially, an 
average shift from obstructed to equivocal zone was observed 
after therapy (table 3). Transvesical and retropubic variants 
of open prostatectomy are effective urodynamically. In 2 
studies46.47 that exclusively involved patients undergoing 
open prostatectomy, average effect is a shift from obstructed 
to unobstructed zone (table 3 and fig. 5). 
ELECTROSURGERY OF THE PROSTATE 
In transurethral resection of the prostate prostatic tissue 
is electroresected from the level of the bladder neck to the 
verumontanum including adenomatous tissue that sur- 
rounds it.43 Prostatic tissue is ideally resected until the sur- 
gical capsule becomes visible. Patient groups in all urody- 
namically evaluated transurethral resection studies have 
moved away from the obstructed zone (fig. 5 and table 
3).9.47-54 In 2 of 9 studies patients ended in the equivocal zone 
aRer treatment.51.52 In only 1 study patients ended just 
above the borderline of the equivocal zone, although in that 
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article intravesical pressure at maximum flow rate instead of 
detrusor pressure at maximum flow rate was reported." The 
parameter urethral resistance factor was measured in 29 
patients before and 3 months after transurethral incision by 
Rollema and van Mastrigt.10 Average urethral resistance 
factor value decreased from 41 to 16 cm. water, which is 
clearly unobstructed. 
The fate of individual patients could be determined from 2 
studies. Kabalin et  al treated 10 patients with average pros- 
tatic volume of 34 cm3.55 All were obstructed preoperatively. 
Six patients ended in the equivocal zone and 4 were unob- 
structed &r treatment. Meyhoff et al studied 34 patients 
with estimated prostatic weights of 25 to 75 gm.47 Of these 27 
were in the obstructed and 7 in the equivocal zone preoper- 
atively. Postoperatively only 3 patients were still obstructed 
and 27 had become unobstructed. The combined data of these 
2 studies show that of 44 patients 84% were obstructed before 
transurethral resection while after the operation only 6% 
were still obstructed and 51% were truly unobstructed. 
Transurethral incision of the bladder neck and transure- 
thral incision of the prostate are procedures that are essen- 
tially the same. Transurethral incision was popularized by 
Orandis6 and her-Warwick.57 The latter introduced the 
term "trapped prostate," indicating the relatively small ob- 
structing prostate that was trapped between bladder neck 
and external sphincter, and that could be released by an 
incision from the ureteral orifices, passing through the blad- 
der neck and the prostatic tissue to the venunontanum. 
Size of the prostate was an important selection criterion in 
these studies, that is a prostate volume of 30 cm? or 
less.48.49.58 In 2 of 3 studies of transurethral incision the 
patients, on average, were initially in the equivocal zone (fig. 
6).48-49 This probably indicates that these studies involved 
considerable numbers of urodynamically unobstructed pa- 
tients. In 2 studiesa,49 patients on average remained in the 
equivocal zone and in 1 other study% they shifted from the 
clearly obstructed area to the equivocal zone. In the latter 
study 93% and 7% of patients were in the obstructed or in the 
equivocal zone, respectively, before the operation, whereas 
aRer the procedure 39% and 32% of the patients were in the 
equivocal or the unobstructed zone, respectively.68 Kelly et 
a159 found a decrease in urethral resistance after transure- 
thral incision but did not report actual pretreatment and 
posttreatment values of maximum flow rate and intravesical 
pressure at maximum flow rate. 
Transurethral electrovaporization of the prostate. Porru et 
a1 used a grooved roller bar electrode with an average current 
setting of 200 to 300 W to evaporate prostatic tissue in 16 
,.. 3,".---- ..__ 
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hC. 5. Effects of open prostatectomy and transqethral e o n  on 
urethral resistance. Average pretreatment data polnts (dosed clrcles) 
WUE&XJ with average posttreatment data p i n k  (open circles) for 
&dies of open prostatectomy (lines a and b) and transurethral resee 
tion ( h e 8  1-9). Numbers and letters of ha correspond to numbers 
and letters used for etu&es of open proatatectomy and transurethral 
resection in table 3. 
FIG. 6. Effects of laser prostatectomy and transurethral incision on 
urethral resistance. Average prehatment data points (closed circles) 
are connected with average posttreatment data points (open circles) for 
studies of laser mtatec@my (lines a-ft and trms~thral incision 
(lines 1 3 ) .  NumLring of hes corresponds to numbenng 0ftranaUre- 
thral incision ~ t u d i e ~  in table 3. Letters of lines o~rre~ponds to letters 
used for studies of laser pmstatectomy in table 4. 
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patients with BPH.W On average the patient group moved 
from obstructed to unobstructed zone on the Abrams- 
GriBths nomogram. The minimal urethral opening pressure 
decreased from 73 to 30 cm. water (table 3). 
NONELECTRICAL FORMS OF HIGH ENERGY DELIVERY TO 
THE PROSTATE 
Laser pmstatectomy. Laser treatment involves energy de- 
livery to prostatic tissue that leads either to tissue coagula- 
tion in the case of side-firing fibers or to vaporization when 
contact laser tips are used. Immediate tissue ablation is 
achieved with the latter technique whereas delayed tissue 
sloughing is the rule in the former.61 Most studies have been 
done with side-firing fibers. ARer laser treatment all patient 
groups have moved away from the obstructed zone (fig. 6 and 
table 4). Average prostatic volumes were reported to be 56,39 
and 40 cm? in studies by Bosch et  al,62 Kabalin et  alS5 and 
Cllmmings et  al,m respectively. In the study of Cannon et al 
the volume was stated to be more than 30 cm.3.64 Particularly 
interesting is an article that looked differentially a t  prostates 
bigger or smaller than 50 ~ m . 3 . ~  (studies of J u g  et al (c) and 
deWildt et al (d), respectively, in fig. 6 and table 4). Men with 
larger prostates were more obstructed at baseline and 
showed relatively moderate urodynamic response to treat- 
ment. One article mentioned pressure-flow study results of 
treatment with a vaporizing contact laser tip.65 These au- 
thors compared 4 different side-firing fibers with the SLT* 
contact tip. Unfortunately it is not entirely clear how many 
patients were followed after treatment but the effects of the 
2 approaches on pressure-flow parameters were statistically 
not significantly different. 
Three studies have reported pre and postoperative values 
of urethral resistance factor and/or minimal urethral opening 
pressure after transurethral ultrasound guided laser induced 
prostatectomy and/or visual laser ablation of the pros- 
tate.62.64.66 After 3 to 6 months the average values of urethral 
resistance factor and minimal urethral opening pressure 
changed from clearly obstructed to clearly unobstructed val- 
ues (table 4). 
Results on individual patients were reported in 4 studies 
involving a total of 159 patients.55,62.66.67 Combined results 
indicate that of these men 128 (81%) were in the obstructed 
zone and 31 (19%) were in the equivocal zone preoperatively. 
Postoperatively only 14 (9%) were still clearly obstructed, 
while 65 (41%) of the patients were truly unobstructed. 
In transurethral microwave thermotherapy tissue destruc- 
tion results from coagulative necrosis that is caused by heat- 
ing the tissue above 44C using a transurethrally placed an- 
tenna mounted in a water cooled probe.= Most of the 
studies69-71 were done with the Prostatront device, which 
operates at  1,296 MHz. Venn et a1 used a different device 
that operated at  434 MHz with a maximum power output of 
50 W.72 They were the only group to report average prostate 
volume of patients, that is 40 cm?. Effects of transurethral 
microwave thermotherapy on pressure-flow parameters are 
summarized in table 4. Manieri et al used the high energy 
version of the software program (ProstasoR version 2.5) with 
maximum power output of 70 W.7l In that study and also in 
1 of the low energy studies69 moderate decrease of urethral 
resistance was noted. In the 2 other low energy studies70.72 
urethral resistance did not decrease. 
In addition to the aforementioned studies, Dahlstrand et a1 
treated 37 patients with the Prostatron device, using Pros- 
tasoR version 2.0 and reported the 6-month results.73 These 
investigators found no statistically significant change of de- 
trusor pressure at  maximum flow rate with baseline value of 
70 and value of 67 cm. water after treatment. They did not 
report maximum flow rates that were measured during 
'cal h e r  Technologies, Oak, Pennsylvania. ; %rn omed, Lyon, France, 
pressure-flow studies. Average values of urethral resistance 
factor and minimal urethral opening pressure decreased 
from 45 to 40 cm. water and from 45 to 41 cm. water, respec- 
tively, in a study of 77 patients treated with the low energy 
pr0gram.70 In 31 patients treated with the high energy pro- 
gram, average values of urethral resistance factor and min- 
imal urethral opening pressure decreased from 41 to 31 cm. 
water and from 42 to 31 cm. water, respectively, which on 
average brings the patients close to unobstructed values.71 
Some investigators have pointed out that although values of 
urethral resistance parameters have not changed signifi- 
cantly after low energy transurethral microwave thermo- 
therapy, there was a decrease in the slope of the linear 
passive urethral resistance relation line.74 Whether this in- 
dicates a relevant effect of the treatment is unclear. 
High intensity focused ultrasound thermoablates prostatic 
tissue by a beam of ultrasound waves that can be focused at a 
selected depth, thus producing a region of high energy densi- 
ty.75 Madersbacher et al have used the transrectal approach 
and reported their results in 28 patients followed for 3 to 6 
months.76 On average the patient p u p  moved h m  just above 
to just below the borderline between obstructed and equivocal 
zone (table 4). Average prostatic volume was not reported. 
Transurethral needle ablation of the prostate uses low 
level radiofrequency energy that is delivered directly into 
selected prostatic areas, producing necrotic lesions inside the 
parenchyma and sparing urethral m u c o ~ a . ~ ~  Preliminary 
urodynamic results were reported by Potts et al, who per- 
formed repeat pressure-flow studies in 39 of 71 treated pa- 
tients after followup of 12 m0nths.~8 Of these patients 79% 
had remained obstructed (table 4). 
MISCELLANEOUS MINIMALLY INVASIVE TREATMENT 
MODALITIES 
Prostate stent. Nielsen et a1 have studied urodynamic ef- 
fects of the Prostakath prostate spiral (table 41.41 This is a 
gold-plated stainless steel stent that is endoscopically in- 
serted into the prostatic urethra to keep the prostatic urethra 
sufficiently wide during voiding. Urethral resistance de- 
creased in 8 of 9 patients after insertion of the spiral. Initially 
8 patients were in the obstructed and 1 in the equivocal zone. 
After treatment 3 patients were still in the obstructed 
zone, while only 1 was truly unobstructed.41 
Balloon dilution. Transurethral balloon dilation of the 
prostate may achieve a decrease in urethral resistance by 
several possible mechanisms, that is disruption of anterior 
and/or posterior commissures of the prostate, loss of elastic 
recoil of the prostatic capsule due to overstretching or ische- 
mic atrophy if blood flow to the prostate is interrupted for a 
sufficiently long time during high pressure inflation of the 
bal10on.~9 Of 3 studies80-82 that reported urodynamic effects 
of balloon dilation, 280.81 have shown a decrease in urethral 
resistance (table 4). On average the patients remained in the 
obstructed zone of the Abrams-Griffiths nomogram. 
One-hour dilution to 22F. One-hour dilation of the urethra 
with a 22F Foley catheter as a sham arm in a comparative 
study of microwave thermotherapy and sham treatment did 
not change urethral resistance (table 4).73 
DISCUSSION 
The compilation of studies presented in this review makes 
it possible to calculate average values of pressure-flow study 
parameters detrusor pressure a t  maximum flow rates and 
maximum flow rate before and after treatment for different 
treatment modalities. Results of these calculations can be 
plotted on an Abrams-Griffiths nomogram for comparison 
(fig. 7). 
Validity of comparisons of urodynamic effects of different 
BPH treatment modalities is somewhat limited by the fact 
that prostatic volumes of patient groups in these studies are 
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FIG. 7. Effects of various treatment modalities for BPH on ure- 
thral resistance. Lines based on average results of studies repre- 
sented in tables 1 to 4. Treatments re resented are open prostatec- 
tomy (line 11, transurethral resection &ne 2), transurethral incision 
(line 3), laser prostatectomy (line 4), transurethral microwave ther- 
motherapy (line 51, a blocker treatment (line 6), androgen depriva- 
tion (line 7) and placebo (line 8). 
generally not known. Theoretically a certain treatment mo- 
dality might be more effective than another above a certain 
prostate volume cutoff but differences in effect on urethral 
resistance might be small or nonexistent when treating 
groups of men with smaller prostates. These issues can be 
resolved only in randomized studies of effects of treatment in 
patient groups with comparable prostatic volumes. 
Interestingly, initial average urethral resistance differs 
between groups of patients treated with various treatment 
modalities (fig. 7). These differences may be due to prostate 
volume driven selection of treatment modality. Patients se- 
lected for transurethral resection are clearly more obstructed 
than those treated with transurethral incision and slightly 
more obstructed than those treated with transurethral mi- 
crowave thermotherapy or laser prostatectomy. Patients se- 
lected for open prostatectomy are on average about as ob- 
structed as patients selected for transurethral resection or 
@-blocker treatment. 
The a-blockers are moderately effective in decreasing ure- 
thral resistance and are more effective than androgen depri- 
vation. Androgen deprivation is somewhat more effective 
than placebo. On average, however, medical treatment does 
not bring patients out of the obstructed zone (fig. 7 and table 
1). The recent finding that androgen deprivation with finas- 
Bride might be more effective in patients with larger pros- 
tate@ cannot be confirmed urodynamically, since a study of 
men with average prostate volume of 50 ~ m . ~  did not show 
statistically significant changes in urethral resistance.19 
hetreatment and posttreatment values of placebo can be 
connected with a short line that runs perfectly parallel to the 
borderline between obstructed and equivocal zone (fig. 7). 
This indicates that there is no change in urethral resistance. 
This is an important finding because it indicates that on 
average pressure-flow studies are reproducible and a sensi- 
tive way of comparing placebo with active treatment. The 
fact that balloon dilation clearly is not more effective than 
medical treatment may be 1 explanation for its rapid decline 
in popularity. Transurethral microwave thermotherapy has 
also led to urodynamic results comparable to results achieved 
with a-blocker treatment. However, this treatment modality 
is still being developed in the sense that progressively higher 
energies may result in better effect, although the first uro- 
dynamic results with high energy software have not been 
mpressive. 7 1 
Lines that connect average pretreatment and posttreat- 
ment values for open prostatectomy, transurethral resection, 
transurethral incision, Laser prostatectomy, transurethral 
microwave thennotherapy and a-blocker treatment run al- 
most perfectly parallel to each other and away from the 
Dbstructed area (fig. 7). Relative lengths of these lines indi- 
cate efficacy of the various methods. Based on this analysis 
and taking the a for ementioned limitations into consider- 
ation, treatment modalities can be ranked according to uro- 
dynamic efficacy. Open prostatectomy seems to be more ef- 
fective than transurethral resection, which again is more 
effective than the almost equally effective duo of laser treat- 
ment and transurethral incision. Then follows a p u p  of 
almost equally effective treatments, that is balloon dilation, 
a-blockers and transurethral microwave thermotherapy. Fi- 
nally, the less effective androgen deprivation outperforms 
placebo treatment. These results are confirmed by studies 
that have used the parameters urethral resistance factor 
andlor minimal urethral opening pressure as a way to ex- 
press urethral resistance (tables 1 to 4). Again, on average, 
medical treatment generally did not make patients truly 
unobstructed, but a-blockers are slightly more effective than 
androgen deprivation in decreasing urethral resistance. The 
urodynamic effect of transurethral microwave thermother- 
apy seems to be comparable to that of a-blocker treatment 
and the results of placebo and watchful waiting studies con- 
firm the reproducibility of pressure-flow studies. 
Clinicians are interested primarily in results obtained in 
individual patients. More than 80% of all patients in urody- 
namic studies of transurethral resection (data available in 2 
studies47-9, transurethral incision (data available in 1 
study9 and laser prostatectomy (data available in 4 stud- 
iesS6, 62, 66.67) were obstructed before treatment. The percent- 
ages of truly unobstructed patients aRer treatment were 
recorded in the following percentages, transurethral resec- 
tion 51%; laser prostatectomy 41% and transurethral inci- 
sion 29%. Available data on androgen deprivation are less 
detailed than data in articles on other modalities. Few pa- 
tients seem to be truly unobstructed after treatment.14.17 
One study of doxazosin (4 mg. per day) indicates results that 
can be achieved in this respect with an a-blocker.= Before 
the start of therapy 74% of the patients were obstructed and 
none was in the unobstructed zone. After 3 months 66% were 
still obstructed and only 5% were in the unobstructed area. 
A dissociation between symptomatic versus urodynamic 
improvement is believed to occur with some newer forms of 
medical or instrumental treatment. As pointed out by Wein, 
there may be several possible explanations for such a phe- 
nomenon.84 It may not be necessary to reduce obstruction to 
an amount similar to prostatectomy to achieve significant 
symptomatic improvement. Alternatively this may indicate 
that symptomatic results will be of short duration or that 
symptoms of prostatism have much less to do with urody- 
namically defined obstruction than we think. 
However, there is a high level of agreement between rank- 
ing of treatment modalities based on the magnitude of uro- 
dynamic improvement as determined in this study and rank- 
ing based on probability and magnitude of symptomatic 
improvement as reported by Roehrborn.85 The rank order for 
probability of symptom improvement was open prostatec- 
tomy, transurethral resection, transurethral incision, a- 
blocker, balloon dilation, placebo, watchful waiting. For the 
magnitude of symptomatic improvement the rank order was 
transurethral resection, open prostatectomy, transurethral 
incision, balloon dilation, a-blocker, placebo, finasteride.85 
This suggests that there may be a correlation between symp 
tomatic and umdynamic improvement. Since only a minority 
of the urodynamic studies reviewed included detailed symp- 
tom score data, it was not possible to investigate indepen- 
dently this question based on data fiom the literature. 
The durability of treatment effect has been determined for 
several modalities by Roehrborn.S5 Probability for re- 
treatment need for open prostatectomy, transurethral resec- 
tion and transurethral incision was 2.3%, 9.8% and 12.9% 
respectively, at 5 years after initial treatment. This rank 
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order also shows clear similarities with that based on urody- 
namic improvement. 
Compared to symptoms and quality of life, which are direct 
outcome measures of treatment, pressure-flow studies are 
indirect measures. The idea that magnitude of short-term 
d y n a m i c  improvement correlates with durability of the 
treatment response should be examined prospectively. Con- 
firmation of this preliminary thought would make the short- 
term d y n a m i c  effect a powerful predictor of durability. In 
that case the urodynamic effect would deserve to be accepted 
as a true treatment outcome. Presently these effects should 
be considered a treatment outcome in relation to treatments 
that claimed to decrease obstruction. 
CONCLUSIONS 
Despite some limitations, treatment modalities can be 
listed in descending order of d y n a m i c  efficacy and open 
pmstatectomy is more effective than transurethral resection. 
These 2 treatments decrease urethral resistance more than 
laser treatment or transurethral incision, which again are 
more effective than balloon dilation, a-blockers or transure- 
thral microwave thermotherapy. Finally, androgen depriva- 
tion performs better than placebo treatment. 
The results of pressure-flow studies in placebo treatment 
arms show that they exhibit good long-term reproducibility. 
Pressure-flow studies are a sensitive way to compare active 
treatment to placebo. There seems to be a relation between 
urodynamic effect and probability as well as magnitude of a 
symptomatic effect of a certain treatment. There also seems 
to be a relation between magnitude of short-term urodynamic 
effect and durability of a treatment modality. 
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